Precision Biosciences (DTIL) Common Equity (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Common Equity data on file, last reported at $76.1 million in Q1 2026.

• Common Equity for Q1 2026 came in at $76.1 million, up 54.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.1 million (up 54.25% YoY), and the FY2025 annual result was $92.2 million, up 63.58% from the prior year.
• Common Equity fell to $76.1 million in Q1 2026 per DTIL's latest filing, from $92.2 million in the prior quarter.
• Over five years, Common Equity peaked at $103.0 million in Q2 2022 and troughed at $16.6 million in Q3 2025.
• A 5-year average of $55.4 million and a median of $56.4 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity jumped 198.99% in 2024, then tumbled 74.36% in 2025.
• A 5-year view of Common Equity shows it stood at $60.4 million in 2022, then sank by 68.79% to $18.9 million in 2023, then jumped by 198.99% to $56.4 million in 2024, then soared by 63.58% to $92.2 million in 2025, then retreated by 17.5% to $76.1 million in 2026.
• Business Quant data shows DTIL's Common Equity at $76.1 million in Q1 2026, $92.2 million in Q4 2025, and $16.6 million in Q3 2025.